Figure 5.
Forest plots of relative risk of all-grade diarrhea (A), all-grade colitis (B), high-grade diarrhea (C) and high-grade colitis (D) associated with a nivolumab/ipilimumab combination versus ipilimumab monotherapy control.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.